SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Storey Robert F)
 

Search: WFRF:(Storey Robert F) > (2005-2009) > Ticagrelor versus c...

  • Wallentin, Lars,1943-Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR) (author)

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • 2009
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-124172
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-124172URI
  • https://doi.org/10.1056/NEJMoa0904327DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding.

Subject headings and genre

  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Becker, Richard C. (author)
  • Budaj, Andrzej (author)
  • Cannon, Christopher P. (author)
  • Emanuelsson, Håkan (author)
  • Held, Claes,1956-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper(Swepub:uu)clahe947 (author)
  • Horrow, Jay (author)
  • Husted, Steen (author)
  • James, Stefan,1964-Uppsala universitet,Institutionen för medicinska vetenskaper,UCR(Swepub:uu)stjam367 (author)
  • Katus, Hugo (author)
  • Mahaffey, Kenneth W. (author)
  • Scirica, Benjamin M. (author)
  • Skene, Allan (author)
  • Steg, Philippe Gabriel (author)
  • Storey, Robert F. (author)
  • Harrington, Robert A. (author)
  • Freij, Anneli (author)
  • Thorsén, Mona (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:New England Journal of Medicine361:11, s. 1045-10570028-47931533-4406

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view